1. A phase 3, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have received treatment with prior anticancer therapies
    The purpose of the study is to assess the safety and effectiveness of the trial drug DCC-2618 in patients with far-advanced gastrointestinal stromal tumors, which have previously been treated with cancer drugs.
    Primary researcher: Panu Jaakkola

  2. The stop-GIST-trial: Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatment. A prospective multicenter phase II trial
    The purpose of the study is to find if imatinib therapy may be discontinued for patients whose tumors have been removed and who have been monitored for a long time while on the medication without GIST progression.
    Primary researcher: Panu Jaakkola

  3. Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomized phase III study
    The purpose of the study is to compare the effectiveness and safety of imatinib therapy lasting three years to imatinib treatment lasting five years.
    Primary researcher: Panu Jaakkola

  4. A randomized phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumor (GIST)
    The purpose of the study is to compare regorafenib administered alternately with imatinib to imatinib as a first-line therapy for patients with a metastatic gastrointestinal stromal tumor (GIST).
    Primary researcher: Panu Jaakkola

 Contact Information
tel. +358 50 427 0680